Research may contribute to the validation of BSP as a tumour biomarker and support the development, characterisation and preclinical evaluation of BSP-targeting inhibitors or antibodies in in vitro and in vivo experiments (e.g. ovariectomised or tumour xenograft model), ultimately aiming for clinical translation. The gene discussed is IBSP; the disease is neoplasm.